NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall

John Carroll

Editor & Founder

Seven years ago, Jay Bradner left high-profile posts at Harvard Med and Dana-Farber and jumped to the leadership role at Novartis’ global research arm, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall

John Carroll

Editor & Founder

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm

NI­BR chief Jay Brad­ner joins the ex­o­dus at No­var­tis, hand­ing the keys to Fiona Mar­shall

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm